Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for evaluating blood coagulation reaction

A technology for coagulation and coagulation factors, which is used in biochemical equipment and methods, microbial determination/inspection, instruments, etc.

Active Publication Date: 2015-09-23
CHUGAI PHARMA CO LTD +1
View PDF14 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the existing FVIII drug efficacy monitoring methods may not be applicable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for evaluating blood coagulation reaction
  • Method for evaluating blood coagulation reaction
  • Method for evaluating blood coagulation reaction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0086] Hereinafter, the present invention is described in more detail through examples, but the present invention is not limited to these examples.

[0087] Preparation of anti-FIXa / FX bispecific antibody with FVIII functional substitution activity and determination of FVIII functional substitution activity

[0088] Anti-FIXa / FX bispecific antibodies with FVIII function substitution activity were obtained using the methods described in WO2005 / 035756, WO2006 / 109592, and WO2012 / 067176. The antibody genes described in WO2005 / 035756, WO2006 / 109592, and WO2012 / 067176 were incorporated into animal cell expression vectors, which were transfected into HEK293 cells to transiently express bispecific antibodies. Subsequently, the bispecific antibody contained in the cell culture supernatant was purified with protein A and filtered.

[0089] The FVIII function substitution activity of thus purified bispecific antibodies was determined by the enzymatic assay shown below. At room temper...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.

Description

technical field [0001] The present invention relates to a method for evaluating coagulation reactions mediated by substances having coagulation factor VIII (FVIII) function substitution activity. In addition, the present invention relates to a reagent for evaluating blood coagulation reaction comprising activated blood coagulation factor XI (FXIa), and a kit for evaluating blood coagulation reaction mediated by a substance having blood coagulation factor VIII (FVIII) function substitution activity comprising the reagent Wait. Background technique [0002] Hemophilia is a bleeding disorder caused by congenital deficiency or insufficiency of coagulation factor VIII (FVIII) or coagulation factor IX (FIX). The former is called hemophilia A and the latter is called hemophilia B. Their genes are all present on the X chromosome, and genetic abnormalities are transmitted through sex-linked recessive inheritance, so more than 99% of the patients are male. The known prevalence is a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/86
CPCG01N2800/224G01N2333/755G01N33/86C12Q1/56C12N9/6443G01N2333/96452
Inventor 添田哲弘北泽刚久岛绿伦
Owner CHUGAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com